Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.

European journal of heart failure·2021

Same author

Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of death.

ESC heart failure·2021

Same author

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.

American heart journal·2021

Same author

Rapid identification of bacteria from respiratory samples of patients hospitalized in intensive care units, with FilmArray Pneumonia Panel Plus.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021

Same author

Comparison of Circulating Immune Cells Profiles and Kinetics Between Coronavirus Disease 2019 and Bacterial Sepsis.

Critical care medicine·2021

Same author

A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients.

EClinicalMedicine·2021

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Inotropes in cardiac patients: update 2011.

John T Parissis¹, Pinelopi Rafouli-Stergiou, Vassilios Stasinos

¹Heart Failure Unit, Attikon University Hospital, Athens, Greece. jparissis@yahoo.com

Current Opinion in Critical Care

|August 17, 2010

Summary

Conventional inotropic agents aid critically ill patients but carry mortality risks. New agents like levosimendan show promise for cardiac dysfunction and septic shock, but require further clinical trials.

More Related Videos

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

Related Experiment Videos

Last Updated: Jun 10, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

Area of Science:

Critical care medicine
Cardiology
Pharmacology

Background:

Intensive care unit (ICU) patients often experience low output syndrome due to cardiac dysfunction, myocardial injury, and inflammation.
Conventional inotropic agents can improve hemodynamics but may increase mortality in critically ill patients.
Novel inotropes offer potential benefits with fewer adverse effects.

Purpose of the Study:

To review the current knowledge on the use of conventional and novel inotropic agents in critically ill patients.
To discuss the application of inotropes in various clinical scenarios within the ICU.
To highlight the potential of new inotropic agents in managing cardiac dysfunction.

Main Methods:

Literature review of current knowledge on inotropic agents.
Analysis of European Society of Cardiology guidelines for inotrope use.
Summary of recent findings on levosimendan, istaroxime, and cardiac myosin activators.

Main Results:

Levosimendan and dobutamine are recommended (IIa, B) for low output syndrome with impaired contractility and congestion.
Levosimendan shows efficacy in post-myocardial infarction dysfunction and septic shock, aiding mechanical ventilation weaning and offering cardioprotection.
Emerging agents like istaroxime and cardiac myosin activators demonstrate potential in experimental and early-phase clinical trials for heart failure.

Conclusions:

Short-term inotropic agent use is vital in acute cardiac care for hemodynamic stability and organ perfusion.
Levosimendan presents a promising option with cardioprotective and inflammatory-modulating effects.
Further large-scale randomized clinical trials are necessary to validate new inotropic agents.